BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 34568242)

  • 1.
    Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
    Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
    Garreta Fontelles G; Pardo Pastor J; Grande Moreillo C
    Br J Clin Pharmacol; 2022 Aug; 88(8):3891-3895. PubMed ID: 35146800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations.
    Brouillard P; Schlögel MJ; Homayun Sepehr N; Helaers R; Queisser A; Fastré E; Boutry S; Schmitz S; Clapuyt P; Hammer F; Dompmartin A; Weitz-Tuoretmaa A; Laranne J; Pasquesoone L; Vilain C; Boon LM; Vikkula M
    Orphanet J Rare Dis; 2021 Jun; 16(1):267. PubMed ID: 34112235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
    Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
    Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
    Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
    Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
    Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
    Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review on Cutaneous and Musculoskeletal Manifestations of CLOVES Syndrome.
    Öztürk Durmaz E; Demircioğlu D; Yalınay Dikmen P; Alanay Y; Alanay A; Demirkesen C; Tokat F; Karaarslan E
    Clin Cosmet Investig Dermatol; 2022; 15():621-630. PubMed ID: 35444443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
    Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
    Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpelisib: A Novel Agent for PIK3CA-Related Overgrowth Spectrum.
    Nadjkovic K; Lonabaugh K
    J Pediatr Pharmacol Ther; 2023; 28(7):590-594. PubMed ID: 38025143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
    Martinez-Lopez A; Blasco-Morente G; Perez-Lopez I; Herrera-Garcia JD; Luque-Valenzuela M; Sanchez-Cano D; Lopez-Gutierrez JC; Ruiz-Villaverde R; Tercedor-Sanchez J
    Clin Genet; 2017 Jan; 91(1):14-21. PubMed ID: 27426476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome.
    López Gutiérrez JC; Lizarraga R; Delgado C; Martínez Urrutia MJ; Díaz M; Miguel M; Triana P
    J Pediatr Adolesc Gynecol; 2019 Dec; 32(6):648-650. PubMed ID: 31330249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of 13 patients with PIK3CA-related overgrowth spectrum using a targeted deep sequencing approach.
    de Kock L; Cuillerier A; Gillespie M; Couse M; Hartley T; Mears W; Bernier FP; Chudley AE; Frosk P; Nikkel SM; Innes AM; Lauzon J; Thomas M; Guerin A; Armour CM; Weksberg R; Scott JN; Watkins D; Harvey S; Cytrynbaum C; ; Kernohan KD; Boycott KM
    Am J Med Genet A; 2024 Mar; 194(3):e63466. PubMed ID: 37949664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PIK3CA-related overgrowth syndrome (PROS)].
    Venot Q; Canaud G
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.
    Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N
    PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
    Emrick LT; Murphy L; Shamshirsaz AA; Ruano R; Cassady CI; Liu L; Chang F; Sutton VR; Li M; Van den Veyver IB
    Am J Med Genet A; 2014 Oct; 164A(10):2633-7. PubMed ID: 25044986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid Arthritis and CLOVES Syndrome: A Tricky Diagnosis.
    Damian L; Lebovici A; Pamfil C; Belizna C; Vulturar R
    Diagnostics (Basel); 2020 Jul; 10(7):. PubMed ID: 32660056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
    Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
    Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrofacial vascular metameric syndrome is caused by somatic pathogenic variants in
    Sheppard SE; Sanders VR; Srinivasan A; Finn LS; Adams D; Elton A; Amlie-Lefond C; Nelson Z; Dmyterko V; Jensen D; Zenner K; Perkins J; Bennett JT
    Cold Spring Harb Mol Case Stud; 2021 Dec; 7(6):. PubMed ID: 34887309
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.